Make smarter decisions on the radiopharmaceuticals market

Radiopharma is hot in 2026, and the industry is starting to consolidate.

We've found a lot of interesting signals. For example, in August 2026, Curium agreed to buy Lantheus, which makes widely used prostate cancer imaging agents, for up to $8B. A month later, Telix agreed to buy ITM, a German developer that also produces the isotope lutetium-177, for $1.65B upfront. The companies that already make and ship radioactive drugs are joining forces to control both the supply and the pipeline.

In this section, we look at why deals are speeding up now, which parts of the chain buyers want most, and what this wave of mergers leaves for smaller developers.

Radioactive drugs can treat cancers that other drugs no longer reach, but getting them to patients is a race against the clock.

We look at six types of companies, from tracer makers and radioligand developers to theranostic platforms, isotope producers and manufacturing networks. Their buyers include hospitals, nuclear medicine centers and the big drugmakers that license their programs. For each, we rank the biggest pains, like doses that decay within days, scarce isotopes such as actinium-225, and too few sites able to give the treatment.

This shows which problems buyers will pay to solve now, and which ones depend on supply that doesn't exist yet.

Radiopharma companies make money in several ways: selling doses per patient, pairing an imaging agent with a matching treatment, licensing programs to big pharma, and selling isotopes or production capacity to other developers.

We compare who pays and what each model costs. A treatment dose sells for a high price, but it has to be made fresh and is lost if the delivery runs late. A diagnostic tracer sells in larger volumes at a lower price, and insurers decide how much hospitals get paid for it. Isotope producers can sign long supply contracts, but they need years and heavy spending to build capacity.

You'll see which models keep their margins when supply is tight, and which ones depend on a partner's pipeline to survive.

Our growth estimate rests on a few forces. Here, we look at each of them.

Some drivers are easy to see: more cancer patients, new targets beyond prostate and neuroendocrine tumors, and big pharma money. Others reinforce each other. Each new imaging agent finds patients who could get the matching treatment. More treatment sites make the next drug easier to launch. And new isotope capacity lowers the risk for developers waiting on supply.

Before building or investing, you should know what it takes to make, ship and give a radioactive drug to many patients, not just to a few in trials.

RayzeBio and Fusion Pharmaceuticals are the names people remember, because big pharma paid billions for them, but they're only a small part of this market.

Plenty of smaller companies do quieter work. Some produce one isotope, like lead-212 or actinium-225, for everyone else. Others design the chemistry that links an isotope to a targeting molecule, or run the local sites that make and deliver doses each morning.

They're hard to compare because one company can be a drug developer, a supplier and a manufacturer at the same time. Many also sell through partners, so their name rarely appears on the drug a patient receives.

Below, you'll find the market grids and ecosystem maps we've built to show who makes what, from the reactor to the patient, and where new players are getting in.

Aktis Oncology, Clarity Pharmaceuticals, SHINE Technologies… a few radiopharma companies are pulling ahead, each in its own way. Their models are still being tested.

Aktis raised $318M in the first biotech IPO of 2026 to take its alpha-emitting drugs through early trials. Clarity pairs two copper isotopes, one to image a tumor and one to treat it, and its prostate cancer imaging agent is in late-stage trials. SHINE produces lutetium-177 and sells it to other developers. One bets on the drug, one on the pairing, one on supply.

We'll look at how these teams secured their isotopes early, chose where in the chain to compete, and found partners willing to pay before a first approval.